This biotech is halting its work with Novo Nordisk and laying off more people

Korro is the latest to rethink its ties with the Danish pharma company.

Dow’s banner day points to investor pivot beyond S&P 500’s top winners

Published: Nov. 11, 2025 at 4:28 p.m. ET The Dow Jones Industrial Average ended Tuesday’s session at…

Why cutting drug prices is pushing Eli Lilly’s stock toward an all-time high

Published: Nov. 11, 2025 at 3:20 p.m. ET Eli Lilly & Co.’s stock is once again in…

She survived breast cancer. Now her AI tool could help you skip annual mammograms.

MIT computer-science professor Regina Barzilay lands on the MarketWatch 25 list of people who are reshaping…

Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.

Published: Nov. 10, 2025 at 8:05 a.m. ET Pfizer Inc. pulled off a comeback win, beating out…

Tech stocks have been leading the market lower. Here’s what may lie ahead.

Also: A bond-market indicator for AI, advice on travel during the government shutdown and a potentially…

Trump rolls out pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk. Analysts say the pact raises more questions than it answers.

Jessica Hall is a retirement reporter for MarketWatch. She was an Age Boom Academy Fellow with…

Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera

Management lowers full-year guidance, warns about competition, launches bid for Metsera.

Medicare recipients may get obesity drugs for just $149 a month under a reported White House deal in the works

The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk…

Pfizer’s revenue falls as COVID sales and vaccine recommendations continue to fade

Last Updated: Nov. 4, 2025 at 9:49 a.m. ETFirst Published: Nov. 4, 2025 at 9:30 a.m. ET Shares…